688373 Stock Overview
A biopharmaceutical company, discovers, develops, and commercialize drugs for unmet medical needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Shanghai MicuRx Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥5.39 |
| 52 Week High | CN¥7.79 |
| 52 Week Low | CN¥3.23 |
| Beta | 0.75 |
| 11 Month Change | 7.37% |
| 3 Month Change | 37.50% |
| 1 Year Change | -28.13% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -18.58% |
Recent News & Updates
Recent updates
Shareholder Returns
| 688373 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -0.6% | -1.9% | -2.8% |
| 1Y | -28.1% | -21.0% | 2.0% |
Return vs Industry: 688373 underperformed the CN Biotechs industry which returned -21% over the past year.
Return vs Market: 688373 underperformed the CN Market which returned 2% over the past year.
Price Volatility
| 688373 volatility | |
|---|---|
| 688373 Average Weekly Movement | 8.3% |
| Biotechs Industry Average Movement | 9.0% |
| Market Average Movement | 8.4% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.6% |
Stable Share Price: 688373 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 688373's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 188 | Yuan Zhengyu | www.micurxchina.com |
Shanghai MicuRx Pharmaceutical Co., Ltd., a biopharmaceutical company, discovers, develops, and commercialize drugs for unmet medical needs. It is developing Contezolid (MRX-I) and Contezoilid acefosamil (MRX-4) oxazolidinone antibiotics for multidrug-resistant gram-positive bacteria; MRX-8 MRX, a polymyxin antibiotic, to target multidrug-resistant Gram-negative bacteria; MRX-5 for multidrug-resistant gram-negative bacteria; MRX-7 for multidrug-resistant gram-positive bacteria; MRX-15 and MRX-17 to treat kidney disease; MRX-18 for the treatment of COVID-19; and MRX-23 for the treatment of tumour. Shanghai MicuRx Pharmaceutical Co., Ltd.
Shanghai MicuRx Pharmaceutical Co., Ltd. Fundamentals Summary
| 688373 fundamental statistics | |
|---|---|
| Market cap | CN¥3.53b |
| Earnings (TTM) | -CN¥467.96m |
| Revenue (TTM) | CN¥120.07m |
29.4x
P/S Ratio-7.5x
P/E RatioIs 688373 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688373 income statement (TTM) | |
|---|---|
| Revenue | CN¥120.07m |
| Cost of Revenue | CN¥21.53m |
| Gross Profit | CN¥98.54m |
| Other Expenses | CN¥566.50m |
| Earnings | -CN¥467.96m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.71 |
| Gross Margin | 82.07% |
| Net Profit Margin | -389.75% |
| Debt/Equity Ratio | 40.4% |
How did 688373 perform over the long term?
See historical performance and comparison